Immune Characterization of the Programmed Death Receptor Pathway in High Risk Prostate Cancer

Clinical Genitourinary Cancer

Volumn 15, Issue 5, 2017, Pages 577-581

  Baas, Wesley ^a   Gershburg, Svetlana ^a   Dynda, Danuta ^a   Delfino, Kristin ^a   Robinson, Kathy ^a   Nie, Daotai ^a   Yearley, Jennifer Holmes ^b   Alanee, Shaheen ^c  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c HENRY FORD HEALTH SYSTEM   (United States)

Author keywords

Expression; High risk; Immunohistochemistry; Immunotherapy; Prostatic neoplasms

Indexed keywords

CD3 ANTIGEN; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; PROSTATE SPECIFIC ANTIGEN; CD274 PROTEIN, HUMAN; PDCD1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; BIOCHEMICAL RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; GLEASON SCORE; HUMAN; HUMAN TISSUE; MALE; METASTASIS; MIDDLE AGED; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RETROSPECTIVE STUDY; TREATMENT OUTCOME; AGED; CANCER GRADING; DOWN REGULATION; GENE EXPRESSION REGULATION; IMMUNOLOGY; METABOLISM; PATHOLOGY; PROSTATE TUMOR; T LYMPHOCYTE;

AGED; B7-H1 ANTIGEN; BIOMARKERS, TUMOR; CD3 COMPLEX; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; PROGRAMMED CELL DEATH 1 RECEPTOR; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; T-LYMPHOCYTES;

EID: 85018314632     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2017.04.002     Document Type: Article

References (20)

1. Thompson, I., Thrasher, J.B., Aus, G., et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 177 (2007), 2106–2131.
2. Abuzallouf, S., Dayes, I., Lukka, H., Baseline staging of newly diagnosed prostate cancer: a summary of the literature. J Urol 171 (2004), 2122–2127.
3. Brahmer, J.R., Tykodi, S.S., Chow, L.Q., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366 (2012), 2455–2465.
4. Dong, H., Zhu, G., Tamada, K., Chen, L., B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 5 (1999), 1365–1369.
5. Freeman, G.J., Long, A.J., Iwai, Y., et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192 (2000), 1027–1034.
6. Topalian, S.L., Hodi, F.S., Brahmer, J.R., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366 (2012), 2443–2454.
7. Latchman, Y., Wood, C.R., Chernova, T., et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2 (2001), 261–268.
8. Konishi, J., Yamazaki, K., Azuma, M., Kinoshita, I., Dosaka-Akita, H., Nishimura, M., B7-H1 expression on non–small-cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res 10 (2004), 5094–5100.
9. Nomi, T., Sho, M., Akahori, T., et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res 13 (2007), 2151–2157.
10. Ohigashi, Y., Sho, M., Yamada, Y., et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res 11 (2005), 2947–2953.
11. Strome, S.E., Dong, H., Tamura, H., et al. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res 63 (2003), 6501–6505.
12. Fife, B.T., Pauken, K.E., Eagar, T.N., et al. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol 10 (2009), 1185–1192.
13. Beer, T.M., Kwon, E.D., Drake, C.G., et al. Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer. J Clin Oncol 35 (2017), 40–47.
14. Gettinger, S.N., Horn, L., Gandhi, L., et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non–small-cell lung cancer. J Clin Oncol 33 (2015), 2004–2012.
15. Patel, S.P., Kurzrock, R., PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther 14 (2015), 847–856.
16. Herbst, R.S., Soria, J.C., Kowanetz, M., et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515 (2014), 563–567.
17. Slovin, S.F., Higano, C.S., Hamid, O., et al. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann Oncol 24 (2013), 1813–1821.
18. Richardsen, E., Ness, N., Melbo-Jorgensen, C., et al. The prognostic significance of CXCL16 and its receptor C-X-C chemokine receptor 6 in prostate cancer. Am J Pathol 185 (2015), 2722–2730.
19. Flammiger, A., Bayer, F., Cirugeda-Kuhnert, A., et al. Intratumoral T but not B lymphocytes are related to clinical outcome in prostate cancer. APMIS 120 (2012), 901–908.
20. Przepiorka, D., Ko, C.W., Deisseroth, A., et al. FDA approval: blinatumomab. Clin Cancer Res 21 (2015), 4035–4039.